Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?

Morquio Disease Clinical Trial

— MorqPreg  

Official title:

Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03150069
• Other study ID #: IRB00088777
• Status: Completed
• Start date: May 10, 2017
• Est. completion date: August 17, 2018

Study information

• Verified date: January 2021
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The present study seeks to interview women with Morquio A and Morquio B syndrome, to explore their concerns surrounding pregnancy and the impact of ERT on their perspectives, in comparison with the control group of Morquio B subjects for whom no ERT treatment exists.

Interviews will be conducted by a health psychologist, in-person or over the telephone. Data will be analyzed using MAXQDA 12.0 software and Grounded Theory. Differences in thematic trends between Morquio A subjects, for whom treatment exists, and a control group of Morquio B subjects, for whom there is no treatment, will be compared.

Description:

The present study seeks to interview women with Morquio A and Morquio B syndrome themselves, to explore and discover their perspectives and concerns surrounding pregnancy and having biological children, the impact of the advent of ERT for Morquio A on their perspectives and concerns in comparison with the control group of Morquio B subjects for whom no ERT treatment exists, as well as what each group is being told by the medical community and others in their lives in this regard.

Interviews will be conducted by a health psychologist, either in-person or over the telephone. We will interview 1) those women with Morquio syndrome who are known to have been pregnant and 2) those women with Morquio syndrome who have not been pregnant and/or chose to adopt children. All information will be kept confidential, except as in accordance with Georgia law relating to reporting of child or elder abuse, suicidal and/or homicidal intent.

Data will be analyzed using MAXQDA 12.0 software to develop code which can be used to describe and compare the data using Grounded Theory. Differences in thematic trends between Morquio A subjects, for whom treatment exists, and a control group of Morquio B subjects, for whom there is no treatment, will be compared.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: August 17, 2018
• Est. primary completion date: August 17, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 15 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Documented clinical diagnosis of either MPS IVA or MPS IVB, based on clinical signs and symptoms, documented reduced fibroblast or leukocyte GALNS enzyme activity or genetic testing confirming diagnosis.

2. Subject is at least 15 years old.

3. Subject is female.

4. Subject is fluent enough in English to complete in-depth interview with PI.

Exclusion Criteria:

1. Patient has a clinically significant disease other than Morquio which would confound the effects of Morquio upon study variables.

2. Any condition that, in the view of the Investigator, places the patient at high risk of poor compliance or of not completing the study.

Related Conditions & MeSH terms

• Morquio Disease
• MPS - Mucopolysaccharidosis
• Mucopolysaccharidoses
• Mucopolysaccharidosis IV

Intervention

Other:
• Interview
In-person or telephone in-depth interview

Locations

Country	Name	City	State
United States	Emory University	Decatur	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
Emory University	BioMarin Pharmaceutical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Completion of in-depth interview	Completion of in-depth interview	Approximately 1 hour